Neboglamine

Italian-origin (Rottapharm) glutamic-acid-derived positive allosteric modulator at an allosteric site of the NMDA glycine co-agonist binding region — mechanistically the cleanest way to raise NMDA tone in an activity-dependent manner without direct agonism, theoretically opposite-direction to memantine. Reached Phase 2 for schizophrenia and cocaine dependence by ~2010-2015 then went quiet; no published cognitive-endpoint readouts in healthy adults; vendor availability has expanded modestly (Umbrella Labs ~$60/g, several research-supplier sources) but anecdotal corpus is essentially nonexistent. For Dylan: SKIP-FOR-NOW. Mechanism interesting, evidence base for cognitive enhancement in healthy 20-year-olds is thin to absent, and the encyclopedia already flagged the TAK-653 + neboglamine stack as too aggressive (two unproven glutamate amplifiers).

Neboglamine is an early-1990s Italian discovery — chemical structure (S)-4-amino-5-[(4,4-dimethylcyclohexyl)amino]-5-oxo-pentanoic acid (a glutamic acid analog), CAS 163000-63-3 (free acid) / 2759182-59-5 (HCl salt), molecular formula C₁₃H₂₄N₂O₃ (MW 256.34). Originally synthesized at Rottapharm SpA (Italy) under codes CR-2249 and XY-2401, formerly named "nebostinel" before adopting "neboglamine" as the INN.

The "glycine PAM" framing in plain English:

The NMDA receptor is a coincidence detector that requires two simultaneous ligand-binding events to open: (1) glutamate at the GluN2 subunit, (2) glycine or D-serine at the GluN1 subunit (the so-called "co-agonist" or "strychnine-insensitive glycine site" — distinct from the strychnine-sensitive glycine receptor that does inhibitory chloride conductance in the spinal cord). Both must be bound. This dual-key design is part of the receptor's natural safety: glutamate alone won't open it.

In schizophrenia (and theoretically in normal aging cognitive decline), there is evidence of NMDA receptor hypofunction — too little NMDA-mediated current per glutamate burst. Multiple drug strategies have tried to raise the glycine-site occupancy to compensate:

1. Direct agonists: glycine itself (3-60 g/day in trials, GI-intolerable), D-serine (60 mg/kg/day, modest effects), D-cycloserine (partial agonist, narrow therapeutic window).
2. Glycine reuptake inhibitors (GlyT1 inhibitors): bitopertin (Roche, failed Phase 3 in schizophrenia), iclepertin/BI 425809 (Boehringer, Phase 3 program in schizophrenia cognitive impairment readouts 2024-2026), sarcosine.
3. DAO inhibitors (raise endogenous D-serine): luvadaxistat (TAK-831, Takeda — Phase 2 in schizophrenia cognitive impairment), sodium benzoate.
4. Allosteric modulators of the glycine site itself: this is neboglamine's category, and it is the smallest category. Most "PAMs of the glycine site" are actually glycine-site agonists with allosteric flavor or full-receptor PAMs. The only real glycine-site allosteric PAM that reached Phase 2 is neboglamine.

What neboglamine actually does (mechanistic studies):

• Binds an allosteric site spatially distinct from the glycine recognition site within the GluN1 ligand-binding domain. Does not displace glycine binding directly.
• Facilitates glycine action: increases [³H]MK-801 binding (an open-channel marker of NMDA activation) in a concentration-dependent manner, with positive cooperativity between glycine and CR-2249 (3-10-30 µM tested concentrations enhanced glycine's effect).
• Reverses kynurenic acid antagonism: kynurenic acid is the endogenous tryptophan-pathway metabolite that antagonizes the glycine site (and the α7 nicotinic receptor), and KYNA is elevated in schizophrenia — neboglamine restores glycine effect even with KYNA present. This is the mechanistic basis for the schizophrenia indication.
• Activity-dependent: PAM behavior means it requires endogenous glycine to do anything. With no glycine around, neboglamine alone does nothing at the receptor. This is the same safety design principle as TAK-653 has at the AMPA receptor — only amplifies what's already happening.
• Reverses scopolamine-induced and electroconvulsive-shock-induced amnesia in rats/mice (passive avoidance paradigms, the original 1996-1997 Lanza et al. work). This is the preclinical cognitive-enhancement signal.
• In rats, neboglamine increased FLI (Fos-like immunoreactivity) in prefrontal cortex similarly to haloperidol and clozapine — the antipsychotic-overlap behavioral signal that motivated the schizophrenia program (Pubmed 20045056, Drago/Caccia/Spada 2010).
• Weak NRI activity at supratherapeutic exposures (>100 mg): at clinical doses (25-75 mg) this is not the dominant mechanism; at higher research-chem doses it would contribute and add a stimulant-flavored confound.

Pharmacokinetics (sparse public data):

• Plasma half-life ~4 hours — reported short, requiring multi-daily dosing for sustained NMDA-tone elevation.
• Poor solubility in the free-acid form; the HCl salt (2759182-59-5) is the practical formulation. Most research-chem product is HCl.
• Oral bioavailability unpublished publicly. Single-dose Phase 1 used 200 mg PO in non-human primate pharmacology; human escalation studies described as completing single-dose and multi-dose phases without published F values.
• Brain penetration confirmed by behavioral and Fos-IR effects after oral dosing in rodents.
• Metabolism / elimination route: not publicly characterized in detail. No CYP-induction or major drug-interaction data published.
• Food interaction studies completed in Phase 1 (per Rottapharm trial registry summary) — neboglamine "safe and well-tolerated within the dose range expected for efficacy" was the published headline; specifics not in public domain.

Mechanistic comparison to adjacent compounds:

The cleanest mechanistic claim for neboglamine is: same direction as TAK-653 (glutamate-system amplification) but at a different receptor in the same dual-key complex. The encyclopedia's prior conclusion ("don't stack two unproven glutamate enhancers") rests on this exact observation.